The mental health industry watchdog Citizens Commission on Human Rights International (CCHR) has warned that organized psychiatry's long history of downplaying risks associated with psychiatric drugs could thwart federal efforts to address overprescribing. The Department of Health and Human Services' May 2026 plan aims to support safe deprescribing and tapering of antidepressants, but CCHR says psychiatry's pattern of limiting full disclosure to patients may weaken these safeguards.
The federal shift toward deprescribing aligns with international concerns, such as the 2024 UK All-Party Parliamentary Group report, which called for deprescribing antidepressants and creating withdrawal support services, according to a press release. Yet some within U.S. psychiatry minimize legitimate concerns about antidepressants, citing workforce shortages and limited beds—a stance CCHR views as a thinly veiled request for more funding. This persists despite mental health spending skyrocketing 241% from $40.9 billion in 2000 to $139.6 billion in 2021, while outcomes worsened, as highlighted in an April 2026 U.S. House Subcommittee roundtable.
Following HHS consumer-protection plans, a psychiatric committee formed in 2025 to counter these initiatives conducted a selective survey at a major psychiatric annual meeting. Of 229 psychiatrists who responded, 94% disagreed that the HHS reforms would help their field. CCHR sees this as an exercise designed to manufacture opposition to deprescribing to protect antidepressant prescribing.
In 2002, a psychiatric leader who now serves as secretary of that committee was president and CEO of a major psychiatric hospital in Maryland, where clinical drug trials were conducted under contracts from multiple pharmaceutical companies, including for "treatment-resistant depression." A high-profile mass shooter was once treated at this hospital, where he was prescribed antidepressants linked to violent and suicidal behavior. In 2004, the psychiatrist formally opposed an FDA Black Box warning on SSRI antidepressants and suicide risk in children, issuing a joint statement expressing deep concern that the warning might have a chilling effect on prescribing. This occurred when at least 100 families in the U.S. had loved ones who committed suicide while taking antidepressants.
In 1991, CCHR's actions prompted an FDA public hearing into antidepressants linked to suicide and violence, where testimony from patients and families was ignored by a panel of psychiatrists. In 2004, CCHR again assisted families who testified before another FDA hearing on antidepressants inducing suicide, contributing to the Black Box suicide warning issued that October. The chief communications officer of the main psychiatric body acknowledged CCHR as an opponent due to its well-publicized campaign, noting the body coordinated with pharmaceutical-funded patient advocacy groups to promote antidepressants.
Such warnings potentially threatened a booming industry. Between 1998 and 2002, some two million commercially insured pediatric beneficiaries were taking antidepressants, with the fastest-growing segment being preschoolers aged 0-5. Today, global sales of antidepressants have reached $15.6 billion. Jan Eastgate, President of CCHR International, said, "For years, the mental health field touted the mantra that depression was caused by a chemical imbalance — a claim CCHR refuted since the first SSRI antidepressant came on the market in 1988."
In 2001, patient materials from a psychiatric professional body stated antidepressants "may be prescribed to correct imbalances in the levels of chemicals in the brain" and are not "habit-forming." In May 2005, CCHR organized a joint letter to the FDA signed by more than 100 doctors stating such advertisements were not supported by science. On June 27, 2005, the senior figure representing this new psychiatric committee appeared on NBC's Today Show and called it "total nonsense" to deny evidence that drugs correct a chemical imbalance, but weeks later admitted to People magazine that there was no lab test to prove a chemical imbalance causes any mental disorder.
In 2021, psychiatric agency materials still suggested that differences in brain chemicals may contribute to depression symptoms. A major 2022 University College London umbrella review in Molecular Psychiatry delivered irrefutable evidence disproving the serotonin theory of depression. Psychiatric organizations have also consistently downplayed risks, including potential violence, now widely recognized. Withdrawal risks were similarly minimized; patients experiencing severe symptoms were often misdiagnosed as relapsing, trapping them in long-term use. The term "antidepressant discontinuation syndrome" emerged from a 1996 pharmaceutical industry-funded meeting to deflect attention from dependency.
In 2026, Psychiatric Times admitted these risks had been routinely denied, minimized, or reframed. Withdrawal effects include brain zaps, cognitive impairment, akathisia, anxiety, irritability, emotional blunting, and impaired concentration. Eastgate warns: "Given this decades-long pattern of downplaying risks, opposing warnings and maintaining pharmaceutical relationships, claims that organized psychiatry will genuinely support the current Administration's deprescribing efforts lack credibility." CCHR urges federal officials to fully implement the HHS plan with strong safeguards for informed consent and deprescribing support.
